Almirall company profile
Company profile
Almirall has 2,108 employees and is headquartered in Barcelona, Spain.
Operating from Barcelona since 1943, Almirall develops and sells products focused on skin health, with its main therapeutic emphasis on skin diseases such as psoriasis, atopic dermatitis, acne and actinic keratosis. Its portfolio also covers cardiovascular, respiratory and nervous system medicines. Sales reach Spain, the rest of Europe, the Middle East, the United States, Asia and Africa. The pipeline includes candidates for psoriatic arthritis and pediatric atopic dermatitis, along with earlier-stage programs in hidradenitis suppurativa and alopecia areata. Collaborations are in place with Evotec, Ichnos, Simcere, Etherna, Novo Nordisk and Eloxx. The company adopted its current name in May 2009, having previously been known as Laboratorios Almirall.
In the fiscal year ended December 2025, revenue reached EUR 1.1 billion, up 12.5% from the prior year, and net income stood at EUR 46.2 million. The company has 2,108 employees and its headquarters are in Barcelona, Spain.
Company facts
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Country
- Spain
- Headquarters
- Ronda General Mitre, 151, 08022, Barcelona
- Employees
- 2,108
- Chief executive
- Carlos Gallardo Piqué
- Founded
- 1943
- Fiscal year
- January - December
- Listing
- ALM · BME
- Currency
- EUR
- ISIN
- ES0157097017
- Website
- almirall.com
Almirall and its competitors
The most similar companies by business and size
| Company | Country | Market cap | Employees | Operating margin | P/E (trailing 12 months) |
|---|---|---|---|---|---|
| AlmirallALM | Spain | $2.53B | 2,108 | 9.6% | 32.1 |
| FagronFAGR | Belgium | $1.9B | 4,880 | 14.3% | 18.8 |
| Siegfried HoldingSFZN | Switzerland | $3.53B | 4,454 | 16.7% | 17.3 |
| Faes FarmaFAE | Spain | $1.73B | 2,677 | 13.0% | 18.7 |
| Laboratorios Farmaceuticos RoviROVI | Spain | $3.93B | 1,950 | 20.2% | 17.4 |
| PharmaNutraPHN | Italy | $875.44M | 128 | 21.7% | 35.0 |
Competitors: same or related industry, same region first, then the closest market capitalization. Market cap converted into US dollars at the latest exchange rates; P/E over the last 12 months, not shown when negative.
